A Phase 2b Clinical Trial of YN001 in Adults With Coronary Atherosclerosis

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 456 participants.

Also called NCT07521007

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 456 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07521007
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Australia, Canada, China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07521007. Randomized; quadruple masking; primary purpose treatment. Start 2026-07-31 (actual); primary completion 2027-07-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Phase 2b Clinical Trial of YN001 in Adults With Coronary Atherosclerosis
Acronym
PURIFY-TIMI 81
Condition
Atherosclerosis
Intervention (Drug)
YN001/Placebo 40mg
Intervention (Drug)
YN001/Placebo 20mg
Intervention (Drug)
YN001/Placebo 0mg
Lead sponsor
Beijing Inno Medicine Co., Ltd. (class: industry)
Collaborator
The TIMI Study Group (class: other)

Record details

Record id
cardio:ct-nct07521007
Content hash
42e390fed7cffcfc26ab98909037237ede5849180ee9008260994730aa195263